In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CareX SA

Division of 7TM Pharma AS

Latest From CareX SA

Deals Shaping the Medical Industry (7/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Teasing Out Next-Generation Diabetes Drugs

Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.

BioPharmaceutical Business Strategies

Transatlantic M&A: The Only Way Out for European Biotechs?

Sonus' proposed acquisition of Synt:em answers the French biotech's call for a financeable owner with upside, preferably in the US. For many European biotech firms, M&A may be their only way out of a financing hold. The Synt:em deal-granted its approved early next year--shows that it's still possible to call favorable deal terms, however.

BioPharmaceutical Europe

Rheoscience AS

Rheoscience focuses on target discovery in diabetes, obesity and the metabolic syndrome. To fund its target discovery activities, the company also provides preclinical research services, offering access to a range of novel animal models for validating experimental data and for use in the preclinical and early clinical phases of the drug discovery process.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • 7TM Pharma AS
  • Senior Management
  • Geoffrey Race, CEO
    Jurgen M Lehmann, PhD, VP, Research & CSO
    Frederic Perraud, Dir., Fin.
  • Contact Info
  • CareX SA
    Phone: (33) 388 15 73 20
    11 rue Humann
    Strasbourg, F-67000